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Experimental Goodpasture’s syndrome in Wistar-Kyoto rats im-
munized with a3 chain of type IV collagen.
Background. Glomerulonephritis and lung hemorrhage of au-
toimmune Goodpasture syndrome develop due to immune reac-
tions against epitope(s) of the non-collagenous (NC1) domain of
a3-chain of type IV collagen [a3(IV) NC1]. Whether thymic
mechanisms have a role in the loss of tolerance to the Goodpas-
ture epitope has not been established. We studied the renal and
pulmonary effects of immunization with different forms (mono-
mer, dimer, or hexamer) of a3(IV) NC1 collagen in Wistar-Kyoto
(WKY) rats, and assessed whether the intrathymic inoculation of
the antigen may protect against anti-GBM disease.
Methods. WKY rats were immunized with bovine a3(IV) mono-
mer, dimer, or hexamer, or with a3(IV) NC1 synthetic peptide.
Renal function, kidney and lung immunohistology, and circulating
and tissue bound antibodies to type IV collagen chains were
analyzed. Effects of intrathymic inoculation of antigen on subse-
quent disease induction were analyzed in WKY rats given a3(IV)
NC1 dimer or GBM preparation intrathymically 48 hours before
immunization.
Results. Proteinuria, linear IgG deposition in GBM, and cres-
centic glomerulonephritis developed in WKY rats immunized
with a3(IV) NC1 dimer or hexamer. Lesions were dose-depen-
dent upon injections of 10 to 100 mg dimer. The a3(IV) NC1
monomer induced less severe proteinuria and no crescents.
Pulmonary hemorrhage was detectable in 35% of rats immunized
with 25 to 100 mg a3(IV) NC1 dimer; a3(IV) synthetic peptide (36
carboxyl terminal) did not induce disease. Rats injected intrathy-
mically with up to 100 mg a3(IV) NC1 dimer or with GBM 48
hours before immunization were not protected against subsequent
development of proteinuria and glomerulonephritis.
Conclusions. These findings document that glomerulonephritis
and lung hemorrhage can be elicited in WKY rats by immunization
with a3(IV) NC1. Failure of the intrathymic inoculation of antigen to
prevent disease suggests that immunological tolerance cannot be
achieved by this intervention, in contrast to other autoimmune
conditions, and may imply independent roles for cellular and hu-
moral nephritogenic pathways in anti-GBM nephritis.
Some forms of human rapidly progressive glomerulone-
phritis and hemorrhagic pneumonitis are induced by auto-
antibodies to human basement membranes (Goodpasture’s
syndrome). During the last three decades several attempts
have been made to develop models that reproduce the
human form of Goodpasture syndrome, to identify the
antigen, and to understand the mechanisms of the autoim-
mune response. At the beginning of 1960, Steblay showed
that sheep injected with crude preparations of either het-
erologous or homologous glomerular basement membrane
(GBM) develop antibodies to the injected antigen, and
rapidly progressive glomerulonephritis. The antibodies bind
to the GBM and incite the inflammatory reaction, as shown
by their ability to transfer the disease to naive sheeps. In
vitro the antibodies react with sheep alveolar basement
membrane, but deposition of immunoglobulin in the lung
and hemorrhagic pneumonitis was not observed in ne-
phritic sheep [1]. In 1984 Sado et al reported that Wistar-
Kyoto (WKY) rats immunized with a glycoprotein purified
from heterologous GBM develop rapidly progressive glo-
merulonephritis and hemorrhagic pneumonitis [2, 3]. The
renal and pulmonary lesions were transferred to naive rats
by autoantibodies isolated from the urine of nephritic rats
[4]. The development of autoimmune glomerulonephritis
in WKY rats was confirmed by others [5, 6].
The antigen of human anti-GBM Goodpasture’s syn-
drome is in the non-collagenous (NC1) globular domain of
type IV collagen [7, 8]. The relevant epitope(s) are present
on the alpha-3 chain of type IV collagen [9, 10]. It has been
reported that rabbits immunized with a3(IV)NC1 dimers–
1 Present address: Harvard Medical School, Beth Israel Deaconess
Medical Center, Nephrology Division, Boston, MA 02215, USA.
Key words: extracellular matrix, dendritic cell, thymocyte, GBM a3(IV)
NC1 peptide, lung hemorrhage, glomerulonephritis, anti-GBM disease.
Received for publication June 26, 1997
and in revised form May 20, 1998
Accepted for publication June 1, 1998
© 1998 by the International Society of Nephrology
Kidney International, Vol. 54 (1998), pp. 1550–1561
1550
but not with a1(IV)/a2(IV) NC1 dimers, or with the NC1
hexamer [a1-a5(IV)NC1 domain]–develop autoantibodies
to a3(IV)NC1, glomerulonephritis and hemorrhagic pneu-
monitis [11].
Autoimmune diseases occur when the immune system loses
its capacity to distinguish between self and non-self [12]. The
thymus appears to play a major role in the development of self
tolerance [13, 14], and also in tolerance to experimental
autoimmune disease [15–21]. Intrathymic injections of myelin
basic protein inhibit the development of experimental auto-
immune encephalomyelitis (EAE) [15–17]. A single intrathy-
mic injection of the major encephalitogenic peptide p71-90
induces antigen-specific systemic tolerance, and inhibits the
induction of rat EAE [17]. Autoimmune diabetes in BB rats
[18, 19] and in mice [20, 21] can also be prevented by thymic
injections of pancreatic islet cells. It is not known whether the
intrathymic inoculation of the Goodpasture antigen may have
similar protective effects against experimental autoimmune
anti-GBM disease.
We studied the autoimmune potential of heterologous
type IV collagen in WKY rats, using the monomer, the
dimer and the hexamer forms of a3(IV) NC1 collagen as
antigenic inoculum. Furthermore, we tested the effect of
intrathymic injections of these antigens on the development
of experimental Goodpasture’s syndrome.
METHODS
Animals
Male WKY rats of 150 to 180 g initial body weight were
obtained from Charles River Italia s.p.a. (Calco, Italy) and
used within 10 to 15 days for these studies (body weight at
baseline 200 to 230 g). Animal care and treatment were
conducted in conformity with the institutional guidelines
that are in compliance with national (D. L. n. 116, G. U.,
suppl 40, 18 Febbraio 1992, Circolare No 8, G. U., 14
Luglio 1994) and international laws and policies (EEC
Council Directive 86/609, OJL 358, Dec 1987; Guide for the
Care and Use of Laboratory Animals, U.S. National Re-
search Council, 1996). All animals were housed in a
constant temperature room with a 12-hour dark/12-hour
light cycle and fed a standard diet.
Preparation of bovine GBM and type IV collagen
domains
Glomerular basement membrane and a3(IV)NC1 hex-
amers from bovine kidney were prepared as previously
described [5, 10, 22, 23]. Glomeruli were isolated from
homogenized cortical tissue using a differential sieving
method. They were sonicated to obtain disrupted glomer-
ular basement membrane suspension that was digested with
collagenase (Worthington CLSPA) at 37°C for 20 hours
with continuous stirring in 0.05 M Hepes buffer (pH 7.5)
with 0.01 M CaCl2, and centrifuged at 100,000 3 g for one
hour. Dimers and monomers of a3(IV)chain were pre-
pared from native bovine hexamer [24, 25] as previously
described [10, 22]. Briefly, the NC1 hexamer was dissoci-
ated, and the dimers were resolved from the monomers on
a Sephacryl-200 column. Dimers were further resolved into
fractions D1 and D2 on a C18 reversed phase HPLC
column, and monomers were likewise resolved into frac-
tions M1, M2, and M3. Fraction D2 contained a3(IV)
dimers (70%) and fraction M2 contained a3(IV) NC1
monomers (100%) [10, 22, 26]. The 36-amino acid peptide
in the C-terminal region was synthetically prepared by the
“tea bag” method as described [10, 22]. The peptide was
not coupled to KLH (keyhole limpet hemocyanine) or any
carrier protein. Briefly, the synthetic peptide was assembled
by coupling on solid phase. A ninhydrin test was used to
determine the coupling efficiency after each step. After
successful coupling, the amino acid was deblocked for the
next round of synthesis. Upon completion of synthesis, the
peptide was cleaved from the resin and the functional
groups deprotected using hydrofluoric acid. The 36-amino
acid peptide was purified using a C18 reversed phase HPLC
column and chemically identified by sequence analysis [26].
Immunization with bovine type IV collagen domains
WKY rats were immunized with the monomer, the dimer
and the hexamer forms of the a3(IV)NC1 domains as
antigenic inoculum according to either one of the following
protocols:
Protocol 1. On day 0 the rats were administered the
antigenic inoculum emulsified with equal volume of com-
plete Freund’s adjuvant (CFA; Sigma Chemical Co., St.
Louis, MO, USA) by foot pad injection, followed by a
subcutaneous injection of 5 3 109 cells of pertussis vaccine
(Michigan Public Health, Lansing, MI, USA). The rats
were sacrificed at days 28 to 35.
Protocol 2. On day 0, by foot pad injection the rats were
given the antigenic inoculum emulsified with equal volume
of CFA, followed by subcutaneous injection of 5 3 109 cells
of pertussis vaccine. Fourteen days later the rats were
injected again in different subcutaneous sites with the same
dose of antigen as given on day 0, emulsified with equal
volume of incomplete Freund’s adjuvant (IFA; Sigma).
Animals were sacrificed at day 35.
Experimental design I
To study the effect of immunization with bovine type IV
collagen peptides on kidney and lung pathology, nine
groups of rats were used (detailed in Table 1). The
experimental groups included animals given bovine a3(IV)
NC1 monomer (group IV), dimer (at increasing doses,
groups V to VIII), and hexamer (group IX) as the antigenic
inoculum accordingly to protocol 1 or protocol 2. Control
groups were rats receiving either no treatment or phos-
phate buffered saline (PBS) instead of the antigen at the
time of immunization.
Twenty-four hour urines were collected in metabolic cages
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on days 0 (baseline), 14, 21, 28 or 35 to measure urinary
protein excretion. At the end of the study blood was collected
for determination of serum creatinine and circulating antibod-
ies to the a3 chain of type IV collagen. At sacrifice kidneys
and lungs were removed and processed for immunofluores-
cence and histological analysis and for detection of type IV
collagen a chain-specific antibodies by ELISA.
Experimental design II
To study the effect of intrathymic inoculation of GBM
antigens on the development of experimental Goodpas-
ture’s syndrome, seven additional groups of WKY rats were
used (Table 2). A series of experiments were designed in a
model of disease induced by a crude GBM preparation.
The rats were injected intrathymically with 500 mg (250 mg
in each lobe) of GBM emulsified in PBS (Group X), or with
PBS alone (Group XI). After 48 hours the rats were
immunized with 20 mg GBM emulsified with equal volume
of CFA by foot pad injection and subcutaneous injections
at different sites. A subcutaneous injection with 5 3 109
cells of pertussis vaccine was given immediately afterwards.
The effects of intrathymic injections of antigen were also
evaluated in rats in which the disease was elicited by using
a3(IV) NC1 dimer as the antigenic inoculum. The rats
received a3(IV) dimer at the dose of 25 mg (Group XII) or
100 mg (Group XIII; 12.5 mg and 50 mg into each thymic
lobe, respectively) dissolved in PBS. Control rats (group
XIV) were injected intrathymically with PBS alone. All rats
were immunized 48 hours later with 25 mg a3(IV) dimer
with the modalities reported in protocol 1.
Additional control experiments were performed to es-
tablish the effect of intrathymic injection of synthetic a3
(IV) chain peptide, which is not nephritogenic per se (as
shown by data reported below), on subsequent develop-
ment of disease. To this purpose rats were injected intra-
thymically with 100 mg (50 mg in each lobe) a3(IV)
synthetic peptide dissolved in PBS (Group XV) or with
PBS (Group XVI). After 48 hours the rats were immunized
with 25 mg a3(IV) dimer with the modalities reported in
protocol 1.
In three rats (Group XVII) the a3(IV) synthetic peptide
(50 mg) was injected in the foot pad according to protocol
1 in order to confirm the absence of nephritogenic potential
of the peptide preparation in our experimental conditions
[10, 22].
Urinary protein excretion
Twenty-four hour urine samples were collected using
metabolic cages and proteinuria determined by the modi-
fied Coomassie blue G dye-binding assay for proteins with
bovine serum albumin as the standard [27].
Elution of antibodies from tissues
After a flush and thorough washing of the organs with
PBS to remove serum contaminants [11], kidneys and lungs
were eluted with 0.025 M citrate buffer, pH 3.2, at room
temperature. After neutralization and centrifugation, the
eluates were concentrated by precipitation with 50% satu-
rated ammonium sulphate and dialyzed against PBS. Fur-
ther concentration was by negative pressure [28].
Enzyme linked immunosorbent assay (ELISA)
For direct ELISA, the plates were coated in triplicate
with 25 ng of antigen in 200 ml of coating buffer. The
antigen used to coat the plates was a mixture of bovine
a3(NC1) dimers and monomers, purifed by HPLC [11, 29].
Tissue eluates were analyzed by using recombinant human
NC1 monomers [30], and they revealed specific reactivity
with recombinant human a3NC1. The plates were incu-
bated for two hours at 37°C or overnight at room temper-
ature. Upon coating, the plates were washed three times at
intervals of five minutes, with 0.15 M NaCl and 0.05%
Tween 20 (washing buffer). After washing, the plates were
blocked with 2% BSA in PBS for 30 minutes at 37°C. Upon
blocking, the plates were again washed with the washing
buffer and then incubated with primary antibody (rat
circulating and tissue bound antibodies, dilution 1:50) in an
appropriate dilution in PBS. The plates were incubated for
one hour at 37°C. After primary antibody incubation the
plates were washed again and subsequently incubated with
the secondary antibody (goat anti-rat IgG) conjugated to
alkaline phosphatase (AP) at 1:5000 dilution in PBS. The
Table 1. Experimental design I
Group
No. of
rats
Immunization
(day 0)
Immunization
(day 14)
I 3 None None
II 3 PBS 1 CFA None
III 3 PBS 1 CFA PBS 1 IFA
IV 2 monomer
10 mg 1 CFA
monomer 10 mg 1 IFA
V 5 dimer 10 mg 1 CFA None
VI 4 dimer 25 mg 1 CFA None
VII 5 dimer 25 mg 1 CFA dimer 25 mg 1 IFA
VIII 5 dimer 50 mg 1 CFA dimer 50 mg 1 IFA
IX 3 hexamer
400 mg 1 CFA
None
Abbreviations are in the Appendix.
Table 2. Experimental design II
Group
No. of
rats
Intrathymic injection
(day 22)
Immunization
(day 0)
X 3 GBM 500 mg GBM 20 mg
XI 4 PBS GBM 20 mg
XII 3 dimer 25 mg dimer 25 mg
XIII 4 dimer 100 mg dimer 25 mg
XIV 4 PBS dimer 25 mg
XV 2 recombinant a 3(IV)
peptide 100 mg
dimer 25 mg
XVI 2 PBS dimer 25 mg
XVII 3 — recombinant a 3(IV)
peptide 100 mg
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plates were incubated for one hour at 37°C. Subsequently,
the plates were again washed thoroughly, and substrate,
disodium p-nitrophenyl phosphate (5 mg/ml) was added.
After color development, the absorbance was measured
using an ELISA autoreader at 405 nm [11, 24].
Histological methods
Samples of renal tissue were fixed in Dubosq-Brazil solu-
tion, dehydrated in alcohol, and embedded in paraffin. Sec-
tions (3 mm) were stained with Masson’s trichrome, hematox-
ylin-eosin (H&E), and periodic acid-Schiff (PAS stain).
Crescents were counted in at least 50 glomeruli randomly
selected in a histologic section from each animal. Crescents
were roughly divided into three groups: (a) circumferential;
(b) those involving about one half of the glomerulus; and (c)
those involving a quarter or less of the glomerulus [5]. Lung
specimens were fixed in 10% buffered formalin and processed
as above. In some animals, lungs were inflated at sacrifice and
fixed in the same fixative. The tissue sections were stained with
H&E and by the Gomori’s Prussian Blue reaction for iron
[31]. The slides were examined independently by two investi-
gators in a blind fashion.
Immunofluorescence microscopy
Specimens of renal cortex and of lung were rapidly
frozen in liquid nitrogen. The tissue fragments were em-
bedded in OCT compound (Miles Laboratory, Ekhart, IL,
USA) and sectioned (4 mm) using a Mikrom 500 O cryostat
(Mikrom, Walldorf, Germany) for direct immunofluores-
cence staining of rat IgG. Sections were fixed in acetone,
blocked with 1% BSA in PBS, and incubated one hour at
room temperature with affinity-purified, fluorescein-conju-
gated goat F(ab9)2 fragments (H1L) anti-rat IgG (Jackson
Immunoresearch, West Grove, PA, USA). After washing in
PBS, slides were mounted using 1% N-propyl gallate in
Tris-HCl 0.1 M, pH 8 to reduce fading, and examined with
an Olympus BH-RFCA2 microscope equipped with epiflu-
orescence using a USH-102D mercury lamp and appropri-
ate optics. The evaluation was performed without knowl-
edge of the group in at least 15 glomeruli from each rat of
each group. The amount and extent of the immune deposits
were semiquantitatively graded on a scale from 0 to 111
(0, absent; 1, minimal; 11, moderate; 111, marked and
extensive) [5].
Electron microscopy
Small specimens of lung tissue were fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) or with
Karnovsky’s solution [32] for four hours at 4°C. Samples
were washed in cacodylate buffer and subsequently post-
fixed in 1% osmium tetroxide for one hour. After a brief
wash in cacodylate buffer, they were dehydrated through
ascending grades of alcohol and embedded in Epon resin.
Sections were cut on an LKB V ultramicrotome. Semithin
sections were stained with toluidine blue in borax and
examined by light microscopy. Ultrathin sections were
stained with uranyl acetate and lead citrate and then
examined with a Zeiss EM 109 electronmicroscope.
RESULTS
The main results are summarized in Tables 3, 4, 5, and 6;
further details are given in the sections below. The gain in
body wt in the animals of the groups immunized with
different a3(IV)NC1 peptides was comparable to control
(final body wts, mean 6 SD; control rats, groups I to III,
307 6 24 g; rats immunized with a3 (IV) peptides, groups
IV to X, 292 6 27 g).
Renal and pulmonary effects of immunization with
bovine a3(IV) NC1 monomer, dimer, and hexamer
Groups I to III. Normal rats and control rats injected with
CFA only or CFA 1 IFA. The values of urinary protein
excretion were within normal range. Kidneys and lungs
showed no histologic or immunohistochemical abnormali-
ties.
Group IV. Rats immunized with a3(IV) NC1 monomer.
These rats had increased urinary protein excretion rates
(approximately 130 mg/day at sacrifice) and mild glomeru-
lar histologic abnormalities mainly consisting of irregular
hypercellularity of tufts and glomerulo-capsular adhesions.
Linear GBM staining for IgG (111) was seen by immu-
nofluorescence (Fig. 1A). Neither pulmonary lesions nor
linear deposition of IgG in the alveolar basement mem-
branes were detectable.
Table 3. Time course of urinary protein excretion (mg/day) in WKY rats immunized with a 3(IV) NC1 monomer, dimer or hexamer
Groups Day 0 Day 7 Day 14 Day 21 Final
I 20.6 6 2.2 17.8 6 2.2 22.9 6 5.2 28.4 6 5.0 23.4 6 4.8
II 19.7 6 2.1 17.3 6 5.1 20.6 6 0.5 21.7 6 2.8 23.8 6 0.7
III 15.8 6 4.5 20.5 6 4.2 16.2 6 3.8 16.5 6 3.3 29.7 6 24.6
IVa 28 ND 42 68 134
V 27.5 6 12.7 19.4 6 5.8 82.3 6 133.9 320.7 6 197.6 520.8 6 161.2
VI 21.5 6 2.2 21.2 6 2.2 168.4 6 100.2 476.5 6 91.4 481.4 6 85.2
VII 39.0 6 16.5 ND 88.5 6 40.0 229.0 6 21.7 385.7 6 213.8
VIII 39.1 6 17.4 ND 100.0 6 14.5 162.0 6 74.0 283.0 6 141.5
IX 20.1 6 3.3 19.6 6 2.4 115.1 6 114.8 315.9 6 231.5 399.2 6 250.8
Values are expressed as mean 6 SD. ND is not determined.
a N 5 2.
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Groups V to VIII. Rats immunized with 10 to 100 mg
a3(IV) NC1 dimer: Proteinuria and renal lesions. These rats
had higher rates of urinary protein excretion as compared
with both control animals and rats of group IV, with
average values of 280 to 520 mg/24 hr at sacrifice. Glomer-
ular damage was present in a dose-dependent fashion.
Thus, most of the affected glomeruli in the rats injected
with 10 mg a3(IV) NC1 dimer (group V) displayed either
glomerulo-capsular adhesions or crescents involving only a
quarter or less of their circumference, whereas almost no
glomeruli (0.2%) had circumferential crescents in this
group. The percentage of glomeruli with circumferential
crescents progressively increased in the rats injected with
total doses of 25, 50, and 100 mg (group VI, 8.0%; group
VII, 16.4%; and group VIII, 20%). The kidneys that were
the most severely damaged also contained fibrocellular
crescents with sclerosis of tufts, tubular casts, and irregular
tubular atrophy. Immunofluorescence staining of kidney
sections for rat IgG (Fig. 1B) revealed linear deposits along
the GBM (111).
Table 4. Time course of urinary protein excretion (mg/day) in WKY rats injected intrathymically with crude GBM, a 3(IV) NC1 dimer or
recombinant a 3(IV) peptide
Groups Day 0 Day 7 Day 14 Day 21 Final
X 13.9 6 3.4 17.0 6 6.4 39.2 6 49.1 76.3 6 8.1 236.7 6 179.6
XI 16.9 6 4.8 20.6 6 5.2 55.8 6 47.0 191.3 6 57.2 149.9 6 32.7
XII 17.8 6 5.3 18.6 6 9.1 36.9 6 24.1 327.0 6 143.7 525.7 6 370.8
XIII 19.5 6 14.7 18.6 6 2.6 29.2 6 37.6 302.2 6 190.4 270.4 6 183.9
XIV 24.8 6 23.4 17.8 6 5.6 21.8 6 18.8 341.9 6 154.2 386.0 6 208.7
XVa 19 ND 77 233 300
XVIa 15 ND 25 212 449
XVII 20.2 6 3.0 22.0 6 2.0 19.8 6 2.1 22.4 6 5.9 16.4 6 2.9
Values are expressed as mean 6 SD. ND is not determined.
a N 5 2.
Table 5. Renal and lung pathology in WKY rats immunized with a 3(IV) NC1 monomer, dimer or hexamer
Groups
I
(N 5 3)
II
(N 5 3)
III
(N 5 3)
IV
(N 5 2)
V
(N 5 5)
VI
(N 5 4)
VII
(N 5 5)
VIII
(N 5 5)
IX
(N 5 3)
Kidney
Glomerular crescents
Circumferential % 0 0 0 0 0.2 6 0.2 8.0 6 4.6 16.4 6 1.8 20.0 6 7.0 0
1/2 Glomerulus % 0 0 0 0 18.6 6 6.7 31.2 6 7.6 25.2 6 4.0 22.0 6 5.8 19.0 6 7.6
1/4 Glomerulus % 0 0 0 0 42.0 6 9.0 46.0 6 6.7 44.4 6 2.6 16.0 6 4.0 69.4 6 8.7
Rat IgG in GBMa 0 0 0 111 111 111 111 111 111
Lung
Hemorragic lesions (%)b 0 0 0 0 0 50 20 40 0
Rat IgG in ACWc 0 0 0 0 0 0 0 20 0
Values are expressed as mean 6 SE. Abbreviations are: GBM, glomerular basement membrane; ACW, alveolar capillary wall; ND, not determined.
a Intensity of linear staining, score 0 to 111
b Percentage of rats with lesions
c Percentage of rats with IF positive staining.
Table 6. Renal and lung pathology in WKY rats immunized with crude GBM, a 3(IV) NC1 dimer or recombinant a 3(IV) peptide
Groups
X
(N 5 3)
XI
(N 5 4)
XII
(N 5 3)
XIII
(N 5 4)
XIV
(N 5 4)
XV
(N 5 2)
XVI
(N 5 2)
XVII
(N 5 3)
Kidney, glomerular crescents
Circumferential % 0 0 0 0.2 6 0.2 1.0 6 0.4 0 1.1 0
1/2 Glomerulus % 8.7 6 2.9 14.5 6 5.4 17.0 6 2.3 19.2 6 3.9 19.7 6 1.2 7.8 20.5 0
1/4 Glomerulus % 55.7 6 10.9 63.5 6 3.4 57.6 6 7.7 41.2 6 1.9 53.5 6 6.5 66.8 62.3 0
Rat IgG in GBMa 111 111 111 111 111 111 111 0
Lung Hemorragic lesions (%)b ND ND 0 0 0 0 0 0
Rat IgG in ACWc ND ND 0 0 0 0 0 0
Values are expressed as mean 6 SE. Abbreviations are: GBM, glomerular basement membrane; ACW, alveolar capillary wall; ND, not determined.
a Intensity of linear staining, score 0 to 111
b Percentage of rats with lesions
c Percentage of rats with IF positive staining.
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Groups V to VIII. Rats immunized with 10 to 100 mg
a3(IV) NC1 dimer: Lung pathology. The histological analy-
sis of lungs from rats injected with 10 mg a3(IV) NC1 dimer
(group V) showed no differences compared to control rats.
In contrast, small hemorrhagic areas were detectable in
lungs from 50% of rats immunized with 25 mg a3(IV) NC1
dimer (group VI; Fig. 2B). Foci of hemorrhagic pneumo-
nitis, characterized by accumulation of erythrocytes and
macrophages containing crystals of hemosiderin, were also
present in the lungs of rats injected with 50 mg (group VII;
Fig. 2C) or 100 mg a3(IV) NC1 dimer (group VIII; Fig.
2D); the percentage of rats with hemorrage was 20% and
40%, respectively. The hemorrhagic lesions were more
evident in these groups as compared with rats immunized
with 25 mg dimer, and they were severe in one of the
animals injected with 100 mg dimer. As shown in Figure 2D,
the presence of hemosiderin in the crystals was confirmed
by positive reaction with Prussian blue staining. Electron
dense structures corresponding to the hemosiderin crystals
were demonstrated by electron microscopy in the cyto-
plasm of macrophages and in the alveolar spaces within
hemorragic lesions (Fig. 3). Overall, 35% of the animals
developed pulmonary hemorragic lesions after immuniza-
tion with 25 to 100 mg a3(IV) NC1 dimer (groups VI to
VIII) in this study. Modest infiltration of mononuclear cells
and thickening of alveolar septa were observed in lungs that
were inflated and artificially distended at sacrifice.
Linear deposits of IgG were not generally detectable in
lungs by immunofluorescence, including most of the lungs
with hemorrhagic lesions. However, linear staining of rat
Fig. 1. Photomicrographs of cryostat sections of kidneys taken from rats immunized with 20 mg a3(IV) NC1 monomer (A), 25 mg a3(IV) NC1 dimer
(B), or 400 mg a3(IV) NC1 hexamer (C), and from a control rat (D). Sections were stained for rat IgG by direct immunofluorescence. Rat IgG is
distributed in linear pattern along the glomerular basement membranes in the glomeruli from rats injected with the bovine a3(IV) NC1 peptides (A,
B, C). No linear deposits of rat IgG are present in control kidney (D) (3500).
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Fig. 2. Pulmonary effects of immunization with bovine a3(IV) NC1 dimer in rats. (A) Normal lung structure in a control rat (H&E, 3150). (B) Section
of lung from a rat immunized with 20 mg a3(IV) NC1 dimer exhibiting foci of hemorrhagic pneumonitis and mild thickening of alveolar septa (PAS;
3150. (C) Rat immunized with 50 mg a3(IV) NC1 dimer. Red blood cells and macrophages containing hemosiderin are present in alveolar spaces
(H&E, 3300). (D) Red blood cells and iron-containing macrophages are present in the alveolar spaces in the lung from a rat immunized with 100 mg
a3(IV) NC1 dimer. The inset shows macrophages containing crystals of hemosiderin (Gomori’s Prussian Blue; 3300; inset 3800).
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IgG in alveolar capillary walls was present in focal areas in
the rat with severe hemorrhagic pneumonitis injected with
100 mg dimer (Fig. 4).
Circulating and tissue-bound antibodies to a3 chain of
type IV collagen
The sera and tissues of rats injected with 25 mg a3(IV)
NC1 dimer were analyzed for the detection of antibodies to
the a3 chain of type IV collagen by ELISA. Antibodies to
the a3 chain of type IV collagen were detected both in
serum and lungs (adsorbance at 405 nm, mean 6 SE; serum,
1.63 6 0.14; lung, 0.38 6 0.02; . fivefold increase com-
pared to control values in groups I to III, 0.31 6 0.11 and
0.07 6 0.01, respectively), and the highest levels were found
in the kidney eluates (1.13 6 0.14, . tenfold increase
compared to control, 0.10 6 0.02).
Specificity of kidney-bound antibodies to a3(IV) NC1
domain
Kidney eluates were analyzed by ELISA for the presence
of antibodies against other type IV collagen NC1 domains
(a1 to a6). As summarized in Figure 5, kidney-bound
antibodies in rats immunized with 25 or 50 mg a3(IV) NC1
dimer bound strongly to the a3(IV) NC1 recombinant
human antigen and had minimal reactivity to other type IV
collagen NC1 domains.
Group IX rats immunized with a3(IV) NC1 hexamer. The
rats had proteinuria, prevalent crescents of small size, and
IgG deposition in their GBMs. None of these animals had
hemorragic pneumonitis or linear IgG deposits in lungs.
Effects of intrathymic injection of bovine GBM or a3(IV)
NC1 domain on the development of anti-GBM disease
Groups X to XIV. A preliminary set of experiments was
performed to establish whether the intrathymic injection of
antigen may protect WKY rats against anti-GBM glomer-
ulonephritis in a model of disease induced by immunization
with bovine GBM. As with the a3(IV) NC1 peptides, the
disease was characterized by proteinuria and formation of
crescents of small size affecting a high percentage of
glomeruli (Table 6, group XI). Cellular and fibrocellular
crescents were associated with increase of mesangial matrix
or partial sclerosis of tufts, and tubular cast formation. The
pretreatment of rats with intrathymic injection of GBM
preparation (group X) did not inhibit proteinuria and renal
lesions in this model.
Similar results were obtained in animals in which anti-GBM
disease was elicited by immunization with 25 mg bovine
a3(IV) NC1 dimer. There was no reduction in the values of
proteinuria and numbers of crescents in animals that received
up to 100 mg a3(IV) NC1 dimer into the thymus. The
formation and linear binding of rat IgG to GBM as detected
by immunofluorescence staining was not inhibited. Effects on
lung disease were not established because none of the animals
developed lung injury in these experiments.
Groups XV to XVII: a3(IV) synthetic peptide. Neither
proteinuria (16.4 6 1.7 mg/day at sacrifice) or signs of renal
and lung injury were detected in animals immunized with
a3(IV) synthetic peptide (group XVII). The rats given
a3(IV) synthetic peptide into the thymus and then immu-
nized with bovine a3(IV) NC1 dimer (group XV), devel-
oped proteinuria and glomerular lesions of comparable
Fig. 3. Rat immunized with 50 mg a3(IV) NC1
dimer. Electron micrograph of an hemorrhagic
area of lung showing red cells, in alveolar
spaces, electron dense crystals of hemosiderin
(arrows), and inflammatory cells (asterisks)
(uranyl acetate and lead citrate; 33,300).
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severity to the rats given intrathymically PBS instead of
a3(IV) synthetic peptide (group XVI).
DISCUSSION
Very few experimental models have been described so
far for human Goodpasture’s syndrome demonstrating that
active immunization with basement membrane antigens is
capable of inducing in association the typical renal and
pulmonary lesions [2, 10, 33]. A purified preparation of
a3(IV) NC1 dimer did so in rabbits by eliciting the
formation and binding of pathogenic antibodies to the
GBM and to the alveolar basement membranes [10]. The
development of rat autoimmune models using purified
antigen is of major relevance in the light of recent thera-
peutic approaches to anti-GBM glomerulonephritis in rats
[3, 5], which may also attenuate lung hemorrhage, and as a
Fig. 4. Immunofluorescence micrographs of sections of lungs taken from rats injected with a3(IV)NC1 dimer or vehicle, stained for rat IgG. No linear
deposits of IgG are seen in the lungs of rats injected with 25 mg a3(IV)NC1 dimer (A) or with vehicle (B). (C) Linear deposits of IgG focally in alveolar
capillary walls of a rat immunized with the highest dose (100 mg) of a3(IV)NC1 dimer (3600).
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model to study antigen-specific forms of prevention and
therapy. We found that the immunization of WKY rats with
soluble a3(IV) peptides induced glomerulonephritis and
hemorrhagic pneumonitis resembling human Goodpas-
ture’s disease. Proteinuria and glomerular extracapillary
lesions were elicited in the animals immunized with a3(IV)
NC1 dimer as antigenic inoculum. The immunization with
a3(IV) NC1 hexamer also caused proteinuria and glomer-
ular lesions in WKY rats, at least with the relatively high
doses used in this study, at variance with the lack of effects
seen in New Zealand White rabbits injected with smaller
amount of hexamer [11]. As in human Goodpasture’s
syndrome and in the rabbit model [11], glomerular damage
induced by the a3(IV) chain in WKY rats was associated
with the formation of circulating anti-a3(IV) NC1 antibod-
ies and linear deposition of rat IgG in glomerular basement
membranes, reflecting the ability of a3(IV) chain antigen
purified from bovine GBM to elicit the production of
anti-GBM antibodies. Findings that antibodies in kidney
eluates were directed against a3(IV) NC1, with minimal
reactivity to other type IV collagen chains, indicated that
only the a3(IV) NC1 domain contained the target
epitope(s) for nephritogenic antibodies in this model. In
contrast to soluble a3(IV) dimer and hexamer purified
from GBM, our data with a3(IV) synthetic peptide in
control experiments confirm previous findings that the
active immunization of WKY rats with synthesized peptide
containing the a3(IV) NC1 epitope did not cause disease,
even despite the formation of anti-peptide epitope antibod-
ies [34]. In this respect, however, a form of anti-GBM
nephritis has been induced most recently in WKY rats by
injection of a3(IV) NC1 domain prepared by recombinant
DNA technology using mammalian cells, that may maintain
the pathogenic behavior of the native peptide [35].
Besides inflammatory changes in glomeruli, focal hem-
orrhagic lesions were detected in lungs of WKY rats
immunized with 25, 50, or 100 mg dimer. No effects on the
lung were seen in rats immunized with 10 mg a3(IV) dimer.
Pulmonary lesions were confined to small foci of hemor-
rage in rats immunized with the dose of 25 mg, and
contained hemosiderin-laden macrophages in rats immu-
nized with 50 or 100 mg dimer. Only the high dose of
a3(IV)dimer (100 mg) induced diffuse and severe hemor-
ragic pneumonitis in one animal. Thus, like in kidney, the
development of severe injury in lung of WKY rats appears
to be dependent on the amount of injected antigen. Linear
deposits of IgG in alveolar capillary walls were only occa-
sionally detectable by immunofluorescence staining of
lungs, this despite the presence of circulating antibodies to
the a3(IV) NC1 domain. In previous studies no linear IgG
deposits were found in the lungs of sheep or rats with
anti-GBM glomerulonephritis [2, 3, 31]. The absence of
IgG deposits was attributed to the presence of the barrier
provided by the not fenestrated alveolar endothelium, that
limits the access of circulating antibodies [36–38]. Studies
have actually shown that the lungs of animals injected with
nephritogenic doses of anti-basement membrane IgG did
not exhibit IgG deposits and hemorrhage unless the per-
meability of the alveolar endothelium was artificially in-
creased by exposure to high concentrations of oxygen [37,
38]. Beside viral infections, volatile hydrocarbons and
smoking may cause alveolar wall injury and in so doing
increase the susceptibility to pulmonary hemorragic mani-
festations [39, 40]. Deposits of heterologous anti-basement
membrane IgG, focal hemorragic lesions and leukocyte
accumulation were also induced in mice by increasing the
permeability of the alveolar capillary wall with injections of
interleukin-2 (IL-2) and interferon-a (IFN-a), polypeptide
mediators generated by activated lymphoid cells and by
cells infected by viruses, thus mimicking human Goodpas-
ture’s disease [41]. Similar pathways of injury may partici-
pate in the development of polmonary lesions in WKY rats
immunized with a3(IV) collagen, particularly cytokines
elaborated by lymphocytes and macrophages that infiltrate
the lung, and possibly released in blood from the inflamed
kidney. However, the precise mechanisms underlying lung
damage in the absence of detectable alveolar basement
membrane deposits of IgG in rats immunized with a3(IV)
dimer remain uncertain, and might involve the participa-
tion of specific T-cells that infiltrate the lung during
antibody-independent immune reactions.
One of the implications in the failure of intrathymic
inoculation of antigen against anti-GBM glomerulonephri-
tis from our data are that the animals did not achieve a
state of immunological tolerance, at least not in pathways
Fig. 5. Specificity of kidney-bound antibodies from rats immunized with
a3(IV) NC1 dimer (groups VI and VII) or hexamer (group IX) and
control (group III). Samples were assayed in triplicate for each rat. Bars
represent three rats per group. Symbols are: (M) control; (f) 25 mg dimer;
(u) 50 mg dimer; (M) hexamer. Values are mean 6 SE.
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critical to tissue injury unlike models of diabetes [18–21],
autoimmune encephalomyelitis [15–17], and allograft rejec-
tion [42] in which such intervention was effective. Evidence
for cell-mediated mechanisms in anti-GBM disease has
emerged from recent studies in rats [6] and mice [43].
However, such nonhumoral mechanisms have role in the
expression of anti-GBM injury in some MHC haplotypes
only, and they seem to be engaged by passive transfer of
syngeneic anti-a3(IV) NC1 antibodies to induce disease
[43]. Whether this applies to the WKY rat is not known,
nor whether to be effective the intrathymic challenge to
antigen should interfere both with humoral and nonhu-
moral pathways. A dissociation of effects was shown in
experimental autoimmune myasthenia gravis, induced in
rats by immunization with acetylcholine receptor, in which
the intrathymic inoculation of antigen had no effect on the
production of anti-acethylcholine receptor antibodies while
inhibiting the proliferative response to the antigen by
lymph node cells [44]. In our model, Goodpasture antigen
was injected intrathymically. In this setting, we speculate
that, due to the possible cryptic nature of Goodpasture
epitopes [8, 19], they may not be processed and presented
by thymic epithelium [45] or by macrophage/dendritic cells
[46]. It is also possible that the relevant CD41/CD81 cell
populations have relatively low-affinity T cell receptors [47,
48]. These factors allow potential autoreactive cells to
survive deletion. Alternatively, dose-related factors may
have importance. Studies using soluble alloantigen in renal
[42] and cardiac [49] transplantation have shown that the
optimal dose of antigen is an important factor for the
tolerogenic efficacy of intrathymic inoculation. This sug-
gests that higher doses of a3(IV) NC1 than available in this
study were required to interfere with the intrathymic
processes that have roles in the production of pathogenic
antibodies and/or autoreactive T cells. It is interesting that
B cells [50–52], as well as CD41Th2 cells providing help
for B cell antibody response in mice [53], are particularly
resistant to tolerance induction so as to require abundant
amounts of antigen in studies of antigen feeding [54–56].
In summary, experimental Goodpasture’s syndrome was
induced in WKY rats by immunization with purified prep-
arations of soluble a3(IV) NC1 peptides. Disease was
characterized by circulating anti-a3(IV) NC1 antibodies,
proteinuria, crescentic glomerulonephritis with linear de-
posits of IgG along glomerular basement membranes, and
foci of lung hemorrhage. Kidney-bound antibodies were
directed against the a3(IV) NC1 domain with minimal
reactivity to the other type IV collagen chains. Glomerular
lesions were dose-dependent, and severe lung hemorrhage
with linear IgG deposits in alveolar capillary walls devel-
oped after injection of 100 mg a3(IV) NC1 dimer. Intra-
thymic inoculation of GBM or soluble a3(IV) NC1 dimer
48 hours before immunization did not prevent disruption of
self-tolerance by active immunization with pathogenic an-
tigen. Further approaches using larger amounts or alterna-
tive forms of antigen should be made to clarify the role of
intrathymic events in experimental Goodpasture’s syndrome
and to design antigen-specific therapies, possibly combined
with depletion of peripheral autoreactive cells (anti-lympho-
cyte serum) or with strategies to block T cell-B cell interac-
tions and consequent formation of pathogenic antibodies.
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APPENDIX
Abbreviations used in this article are: AP, alkaline phosphatase; BSA,
bovine serum albumin; CFA, complete Freund’s adjuvant; EAE, experi-
mental autoimmune encephalomyelitis; ELISA, enzyme-linked immu-
nosorbent assay; GBM, glomerular basement membrane; H&E, hematox-
ylin-eosin stain; HPLC, high-pressure liquid chromatography; IFA,
incomplete Freund’s adjuvant; KLH, keyhole limpet hemocyanine; NC1,
non-collagenous domain; PAS, periodic acid Schiff stain; PBS, phosphate
buffered saline; WKY, Wistar-Kyoto rat.
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